Peripheral blood leukocyte NO production and oxidative stress in multiple sclerosis

Multiple Sclerosis

Volumn 14, Issue 2, 2008, Pages 159-165

  Koch, Marcus ^a   Mostert, Jop ^a   Arutjunyan, Alexander ^b   Stepanov, Michael ^b   Teelken, Albert ^a   Heersema, Dorothea ^a   De Keyser, Jacques ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b D O OTT RESEARCH INSTITUTE OF OBSTETRICS   (Russian Federation)

Author keywords

leukocytes; multiple sclerosis; nitric oxide; oxidative stress

Indexed keywords

1,1 DIPHENYL 2 PICRYLHYDRAZYL; FREE RADICAL; NITRIC OXIDE;

ADULT; AGE DISTRIBUTION; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE DURATION; FEMALE; HUMAN; LEUKOCYTE; MALE; MULTIPLE SCLEROSIS; OXIDATIVE STRESS; RELAPSE; REMISSION;

ADULT; FEMALE; HUMANS; HYDROGEN PEROXIDE; INDICATORS AND REAGENTS; LEUKOCYTES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NITRIC OXIDE; NITRITES; OXIDATIVE STRESS; PICRATES;

EID: 43149110870     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458507082075     Document Type: Article

References (41)

1. Smith K., Lassmann H. The role of nitric oxide in multiple sclerosis. Lancet Neurol 2002; 1: 232-41.
2. Yamashita T., Ando Y., Obayashi K., Uchino M., Ando M. Changes in nitrite and nitrate (NO2-/NO3-) levels in cerebrospinal fluid of patients with multiple sclerosis. J Neurol Sci 1997; 153: 32-4.
3. Giovannoni G. Cerebrospinal fluid and serum nitric oxide metabolites in patients with multiple sclerosis. Mult Scler 1998; 4: 27-30.
4. Brundin L., Morcos E., Olsson T., Wiklund N., Andersson M. Increased intrathecal nitric oxide formation in multiple sclerosis; cerebrospinal fluid nitrite as activity marker. Eur J Neurol 1999; 6: 585-90.
5. Svenningsson A., Petersson A., Andersen O., Hansson G. Nitric oxide metabolites in CSF of patients with MS are related to clinical disease course. Neurology 1999; 53: 1880-2.
6. Yuceyar N., Taskiran D., Sagduyu A. Serum and cerebrospinal fluid nitrite and nitrate levels in relapsing-remitting and secondary progressive multiple sclerosis patients. Clin Neurol Neurosurg 2001; 103: 206-11.
7. Miljkovic D., Drulovic J., Trajkovic V., Mesaros S., Dujmovic I., Maksimovic D., et al. Nitric oxide metabolites and interleukin-6 in cerebrospinal fluid from multiple sclerosis patients. Eur J Neurol 2002; 9: 413-8.
8. Acar G., Idiman F., Idiman E., Kirkali G., Cakmakci H., Ozakbas S. Nitric oxide as an activity marker in multiple sclerosis. J Neurol 2003; 250: 588-92.
9. Danilov A., Andersson M., Bavand N., Wiklund N., Olsson T., Brundin L. Nitric oxide metabolite determinations reveal continuous inflammation in multiple sclerosis. J Neuroimmunol 2003; 136: 112-8.
10. Rejdak K., Eikelenboom M., Petzold A., Thompson E., Stelmasiak Z., Lazeron R., et al. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology 2004; 63: 1439-45.
11. Giovannoni G., Heales S., Silver N., O'Riordan J., Miller R., Land J., et al. Raised serum nitrate and nitrite levels in patients with multiple sclerosis. J Neurol Sci 1997; 145: 77-81.
12. Nazliel B., Taskiran D., Irkec C., Kutay F., Pogun S. Serum nitric oxide metabolites in patients with multiple sclerosis. J Clin Neurosci 2002; 9: 530-2.
13. Giovannoni G., Silver N., O'Riordan J., Miller R., Heales S., Land J., et al. Increased urinary nitric oxide metabolites in patients with multiple sclerosis correlates with early and relapsing disease. Mult Scler 1999; 5: 335-41.
14. Sarchielli P., Orlacchio A., Vicinanza F., Pelliccioli G., Tognoloni M., Saccardi C., et al. Cytokine secretion and nitric oxide production by mononuclear cells of patients with multiple sclerosis. J Neuroimmunol 1997; 80: 76-86.
15. Beenakker E., Oparina T., Hartgring A., Teelken A., Arutjunyan A., De Keyser J. Cooling garment treatment in MS: clinical improvement and decrease in leukocyte NO production. Neurology 2001; 57: 892-4.
16. Ramsaransing G., Teelken A., Arutjunyan A., De Keyser J. Peripheral blood leukocyte NO production in MS patients with a benign vs progressive course. Neurology 2004; 62: 239-42.
17. Smith KJ, Kapoor R., Felts PA Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 1999; 9: 69-92.
18. Hunter MI, Nlemadim BC, Davidson DL Lipid peroxidation products and antioxidant proteins in plasma and cerebrospinal fluid from multiple sclerosis patients. Neurochem Res 1985; 10: 1645-52.
19. Glabinski A., Tawsek NS, Bartosz G. Increased generation of superoxide radicals in the blood of MS patients. Acta Neurol Scand 1993; 88: 174-7.
20. Naidoo R., Knapp ML Studies of lipid peroxidation products in cerebrospinal fluid and serum in multiple sclerosis and other conditions. Clin Chem 1992; 38: 2449-54.
21. Koch M., Ramsaransing G., Arutjunyan A., Stepanov M., Teelken A., Heersema D., et al. Oxidative stress in serum and peripheral blood leukocytes in patients with different disease courses of multiple sclerosis. J Neurol 2006; 253: 483-7.
22. Koch M., Mostert J., Arutjunyan A., Stepanov M., Teelken A., Heersema D., et al. Plasma lipid peroxidation and progression of disability in multiple sclerosis. Eur J Neurol 2007; 14: 529-33.
23. Percy A., Brady R. Metachromatic leukodystrophy: diagnosis with samples of venous blood. Science 1968; 161: 594-5.
24. Lowry O., Rosebrough N., Farr A., Randall R. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-75.
25. Green L., Wagner D., Glogowski J., Skipper P., Wishnok J., Tannenbaum S. Analysis of nitrate, nitrite, and [15 N]nitrate in biological fluids. Anal Biochem 1982; 126: 131-8.
26. Kostiuk V., Potapovich A., Lunets E. Spectrophotometric evaluation of diene conjugates. Vopr Med Khim 1984; 30: 125-7.
27. Anisimov V., Ukraintseva S., Anikin I., Popovich I., Zabezhinski M., Bertsein L., et al. Effects of phentermine and phenformin on biomarkers of aging in rats. Gerontology 2005; 51: 19-28.
28. Burmistrov S., Oparina T., Prokopenko V., Arutiunian A. Antioxidant activity of the blood serum in pregnant and nonpregnant women: comparison of various detection methods. Klin Lab Diagn 1997; 11: 14-17.
29. Kosov M., Prokopenko V., Oparina T., Evsiukova I., and Arutiunian A. Free radical oxidation and antioxidant system in healthy full-term newborns. Fiziol Cheloveka 2001; 27: 133-6.
30. Gilgun-Sherki Y., Melamed E., Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 2004; 251: 261-8.
31. Adcock I., Brown C., Kwon O., Barnes P. Oxidative stress induces NF kappa B DNA binding and inducible NOS mRNA in human epithelial cells. Biochem Biophys Res Commun 1994; 199: 1518-24.
32. Han Y., Kwon Y., Chung H., Lee S., Simmons R., Billiar T., et al. Antioxidant enzymes suppress nitric oxide production through the inhibition of NF-kappa B activation: role of H(2)O(2) and nitric oxide in inducible nitric oxide synthase expression in macrophages. Nitric Oxide 2001; 5: 504-13.
33. Polytarchou C., Papadimitriou E. Antioxidants inhibit angiogenesis in vivo through down-regulation of nitric oxide synthase expression and activity. Free Radical Res 2004; 38: 501-8.
34. Sastre-Garriga J., Comabella M., Brieva L., Rovira A., Tintoré M., Montalban X. Decreased MMP-9 production in primary progressive multiple sclerosis patients. Mult Scler 2004; 10: 376-80.
35. Ogawa K., Chen F., Kuang C., Chen Y. Suppression of matrix metalloproteinase-9 transcription by transforming growth factor-beta is mediated by a nuclear factor-kappaB site. Biochem J 2004; 381: 413-22.
36. Rhee JW, Lee KW, Kim D., Lee Y., Jeon OH, Kwon HJ, et al. NF-kappaB-dependent regulation of matrix metalloproteinase-9 gene expression by lipopolysaccharide in a macrophage cell line RAW 264.7. J Biochem Mol Biol 2007; 40: 88-94.
37. Rhee JW, Lee KW, Sohn WJ, Lee Y., Jeon OH, Kwon HJ, et al. Regulation of matrix metalloproteinase-9 gene expression and cell migration by NF-kappa B in response to CpG-oligodeoxynucleotides in RAW 264.7 cells. Mol Immunol 2007; 44: 1393-1400.
38. Taylor-Robinson A., Liew F., Severn A., Xu D., McSorley S., Garside P., et al. Regulation of the immune response by nitric oxide differentially produced by T helper type 1 and T helper type 2 cells. Eur J Immunol 1994; 24: 980-4.
39. De Caterina R., Libby P., Peng H., Thannickal V., Rajavashisth T., Gimbrone MA J., et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995; 96: 60-8.
40. O'Brien N., Charlton B., Cowden W., Willenborg D. Nitric oxide plays a critical role in the recovery of Lewis rats from experimental autoimmune encephalomyelitis and the maintenance of resistance to reinduction. J Immunol 1999; 163: 6841-7.
41. Kahl K., Zielasek J., Uttenthal L., Rodrigo J., Toyka K., Schmidt H. Protective role of the cytokine-inducible isoform of nitric oxide synthase induction and nitrosative stress in experimental autoimmune encephalomyelitis of the DA rat. J Neurosci Res 2003; 73: 198-205.